美国老年人接种佐剂重组带状疱疹疫苗的成本效果
本研究采用多队列马尔可夫模型,比较佐剂重组带状疱疹疫苗(RZV)与不接种及与减毒活带状疱疹疫苗(ZVL)在美国60岁及以上及50岁及以上人群中的成本效果。模型估计,与不接种相比RZV可预防103603例带状疱疹、11197例带状疱疹后神经痛(PHN)及14455例其他并发症,每获得一个质量调整生命年的增量成本为11863美元;
要点
- RZV较不接种可预防103603例带状疱疹与11197例PHN,增量成本为每质量调整生命年11863美元。
- 结果在广泛敏感性分析中保持稳健,RZV在60岁及以上人群中较不接种具成本效果、较ZVL可节省成本。
核心结论
- 在美国60岁及以上人群中,接种RZV与不接种相比具成本效果,与ZVL相比可节省成本。
研究设计与样本
- RZV第二剂依从性假设为69%,两种疫苗的功效与衰减参数均来自临床试验,流行病学参数、成本与效用模型输入来自美国特异性人群数据。
- 成本与结局按每年3%贴现,并开展确定性敏感性分析、概率敏感性分析、情景分析与阈值分析。
主要发现
- 与不接种相比,RZV可预防103603例带状疱疹、11197例PHN和14455例其他并发症,社会视角下每获得一个质量调整生命年的增量成本为11863美元。
- 结果在广泛敏感性分析中保持稳健。
临床怎么用
- 作者认为在美国60岁及以上人群中,接种RZV较不接种具成本效果、较ZVL可节省成本。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In the United States, herpes zoster (HZ) and related complications are estimated to result in approximately $1.3 billion in medical care costs and $1.7 billion in indirect costs annually. In this study, we compared the cost-effectiveness of a new Adjuvanted Recombinant Zoster Vaccine (RZV), containing recombinant varicella-zoster virus glycoprotein E and the AS01B Adjuvant System, versus No Vaccine, as well as versus the live attenuated HZ vaccine (Zoster Vaccine Live (ZVL)) in subjects aged 60+ years of age (YOA) and other age cohorts aged 50+ YOA. A multi-cohort Markov model was developed which follows 1 million individuals over their remaining lifetimes from the year of vaccination with annual cycle lengths. Second dose compliance for RZV was assumed to be 69%. Efficacy and waning parameters were derived from clinical trials for both vaccines. Epidemiological parameters, costs and utility model inputs were derived from US-specific population-based data. Costs and outcomes were discounted at 3% per year. Deterministic and probabilistic sensitivity analysis, along with scenario and threshold analysis were carried out to explore the overall uncertainty in the model. The model estimated that, compared to No Vaccine against HZ, RZV would prevent 103,603 HZ cases, 11,197 postherpetic neuralgia (PHN) cases, and 14,455 other complications, at an incremental cost of $11,863 per quality-adjusted life-year saved from a societal perspective. Compared to ZVL, the model estimated that, RZV would prevent 71,638 additional HZ cases, 6403 PHN cases, and over 10,582 other complications, resulting in net total societal cost savings of over $96 million. The results were robust to a wide range of sensitivity analyses. Vaccination against HZ with RZV is cost-effective compared to No Vaccine and cost-saving compared to ZVL, in the US population aged 60+ YOA. Clinicaltrial.gov. registered#: NA.
引用
- Curran D, Patterson B, Varghese L, et al. Cost-effectiveness of an Adjuvanted Recombinant Zoster Vaccine in older adults in the United States. Vaccine. 2018. PMID: 30017145. doi:10.1016/j.vaccine.2018.07.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。